Ventricular assistance system developer CH Biomedical closed a Baheal-backed series D round while peer-to-peer lending platform Alami secured $17.5m in a round led by EV Growth.

Funding

China-based ventricular assistance device developer CH Biomedical has completed a series D round of undisclosed size featuring pharmaceutical commercialisation firm Baheal Pharmaceutical Group, DealStreetAsia reported on Friday. Sequoia Capital China led the round, investing with Lake Bleu Capital, Linden Asset Group, Longmen Capital and HosenCare Brothers. The company had reportedly closed six earlier rounds and its earlier investors included Baheal, HosenCare Brothers, Oriza Seed Capital, FC Capital, Share Capital and Xiyee Asset.

EV Growth, the joint venture formed by…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Robert Lavine

Robert Lavine is special features editor for Global Venturing.
Email LinkedIn